Both Novo Nord's Dual GIP/GLP-1 and copyright are innovative medications designed for managing diabetes and promoting slimming. However, they work through slightly different processes . Semaglutide is a GLP-1 receptor site activator , while Zepotide acts as a dual GIP and GLP-1 agonist , potentially offering a greater impact on combined glycemic… Read More